| Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations MJ Mair, JM Berger, AS Berghoff, AM Starzer, G Ortmayr, HC Puhr, ... JAMA oncology 8 (1), 106-113, 2022 | 60 | 2022 |
| A basic review on systemic treatment options in WHO grade II-III gliomas MJ Mair, M Geurts, MJ van den Bent, AS Berghoff Cancer treatment reviews 92, 102124, 2021 | 59 | 2021 |
| Neurological complications of cancer immunotherapy P Roth, S Winklhofer, AMS Müller, R Dummer, MJ Mair, D Gramatzki, ... Cancer Treatment Reviews 97, 102189, 2021 | 49 | 2021 |
| Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events–a retrospective cohort study MJ Mair, JM Berger, M Mitterer, M Gansterer, AC Bathke, W Trutschnig, ... European Journal of Cancer 165, 184-194, 2022 | 34 | 2022 |
| Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron MJ Mair, M Mitterer, P Gattinger, JM Berger, W Trutschnig, AC Bathke, ... Cancer Cell 40 (5), 444-446, 2022 | 32 | 2022 |
| Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma MJ Mair, A Wöhrer, J Furtner, A Simonovska, B Kiesel, S Oberndorfer, ... Journal of Neuro-oncology 148, 187-198, 2020 | 31 | 2020 |
| LAG-3 expression in the inflammatory microenvironment of glioma MJ Mair, B Kiesel, K Feldmann, G Widhalm, K Dieckmann, A Wöhrer, ... Journal of Neuro-oncology 152, 533-539, 2021 | 28 | 2021 |
| Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours MJ Mair, R Bartsch, E Le Rhun, AS Berghoff, PK Brastianos, J Cortes, ... Nature Reviews Clinical Oncology 20 (6), 372-389, 2023 | 24 | 2023 |
| Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG) M Preusser, A Silvani, E Le Rhun, R Soffietti, G Lombardi, JM Sepulveda, ... Neuro-oncology 24 (5), 755-767, 2022 | 24 | 2022 |
| Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases AM Starzer, A Steindl, MJ Mair, C Deischinger, A Simonovska, G Widhalm, ... British journal of cancer 124 (7), 1294-1300, 2021 | 21 | 2021 |
| Emerging systemic treatment options in meningioma MJ Mair, AS Berghoff, PK Brastianos, M Preusser Journal of Neuro-oncology 161 (2), 245-258, 2023 | 19 | 2023 |
| Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours MJ Mair, S Pajenda, A Ilhan-Mutlu, A Steindl, B Kiesel, G Widhalm, ... ESMO open 5 (6), e000863, 2020 | 19 | 2020 |
| Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance B Englinger, M Mair, W Miklos, C Pirker, T Mohr, S Van Schoonhoven, ... British journal of cancer 116 (4), 489-500, 2017 | 17 | 2017 |
| Prognostic factors in adult brainstem glioma: a tertiary care center analysis and review of the literature A Leibetseder, J Leitner, MJ Mair, S Meckel, JA Hainfellner, M Aichholzer, ... Journal of Neurology, 1-17, 2022 | 16 | 2022 |
| Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases A Steindl, D Alpar, G Heller, MJ Mair, B Gatterbauer, K Dieckmann, ... ESMO open 6 (2), 100057, 2021 | 15 | 2021 |
| High levels of anti–SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine D Fong, MJ Mair, M Mitterer European Journal of Cancer 154, 4-6, 2021 | 13 | 2021 |
| Immunotherapy for brain metastases and primary brain tumors AM Di Giacomo, MJ Mair, M Ceccarelli, A Anichini, R Ibrahim, M Weller, ... European Journal of Cancer 179, 113-120, 2023 | 12 | 2023 |
| Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma MJ Mair, A Ilhan-Mutlu, S Pajenda, B Kiesel, A Wöhrer, G Widhalm, ... Cancer Immunology, Immunotherapy 70 (12), 3643-3650, 2021 | 11 | 2021 |
| PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group NL Albert, N Galldiks, BM Ellingson, MJ van den Bent, SM Chang, ... The Lancet Oncology 25 (1), e29-e41, 2024 | 9 | 2024 |
| Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive … SLN Maas, P Sievers, DC Weber, M Weller, MJ van den Bent, MJ Mair, ... Acta Neuropathologica 146 (6), 837-840, 2023 | 6 | 2023 |
